nach oben

Neurotoxicity Research

Erschienen in:

01.08.2021 | Original Article

MAM-2201, One of the Most Potent—Naphthoyl Indole Derivative—Synthetic Cannabinoids, Exerts Toxic Effects on Human Cell-Based Models of Neurons and Astrocytes

verfasst von: T Coccini, U De Simone, D Lonati, G Scaravaggi, M Marti, CA Locatelli

Erschienen in: Neurotoxicity Research | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Considering the consequences on human health, in general population and workplace, associated with the use of new psychoactive substances and their continuous placing on the market, novel in vitro models for neurotoxicology research, applying human-derived CNS cells, may provide a means to understand the mechanistic basis of molecular and cellular alterations in brain. Cytotoxic effects of MAM-2201, a potent-naphthoyl indole derivative-synthetic cannabinoid, have been evaluated applying a panel of human cell-based models of neurons and astrocytes, testing different concentrations (1–30 µM) and exposure times (3–24-48 h). MAM-2201 induced toxicity in primary neuron-like cells (hNLCs), obtained from transdifferentiation of mesenchymal stem cells derived from human umbilical cord. Effects occurred in a concentration- and time-dependent manner. The lowest concentration affecting cell viability, metabolic function, apoptosis, morphology, and neuronal markers (MAP-2, NSE) was 5 μM, and even 1 μM induced apoptosis. Effects appeared early (3 h) and persisted after 24 and 48 h. Similar behavior was evidenced for human D384-astrocytes treated with MAM-2201. Differently, human SH-SY5Y-neurons, both differentiated and undifferentiated, were not sensitive to MAM-2201. On D384, the different altered endpoints were reversed, attenuated, or not antagonized by AM251 indicating that CB1 receptors may partially mediate MAM-2201-induced cytotoxicity. While in hNLCs, all toxic effects caused by MAM-2201 were apparently unrelated to CB-receptors since they were not evidenced by immunofluorescence. The present in vitro findings demonstrate the cytotoxicity of MAM-2201 on human primary neurons (hNLCs) and astrocytes cell line (D384), and support the use of these cellular models as species-specific in vitro tools suitable to clarify the neurotoxicity mechanisms of synthetic cannabinoids.

Nur mit Berechtigung zugänglich

Alexandre J, Carmo H, Carvalho F, Silva JP (2020) Synthetic cannabinoids and their impact on neurodevelopmental processes. Addict Biol 25(2):e12824. https://doi.org/10.1111/adb.12824CrossRefPubMed

Atwood BK, Huffman J, Straiker A et al (2010) JWH018, a common constituent of ‘Spice’ herbal blends, is a potent and efficacious cannabinoid CB receptor agonis. Br J Pharmacol 160(3):585–593. https://doi.org/10.1111/j.1476-5381.2009.00582.xCrossRefPubMedPubMedCentral

Auwärter V, Dresen S, Weinmann W et al (2009) ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 44:832–837CrossRef

Balmforth AJ, Ball SG, Freshney RI et al (1986) D-1 dopaminergic and β-adrenergic stimulation of adenylate cyclase in a clone derived from the human astrocytoma cell line G-CCM. J Neurochem. https://doi.org/10.1111/j.1471-4159.1986.tb00670.xCrossRefPubMed

Beilmann M, Boonen H, Czich A et al (2019) Optimizing drug discovery by investigative toxicology: current and future trends. ALTEX 36:289–313. https://doi.org/10.14573/altex.1808181

Bénard G, Massa F, Puente N et al (2012) Mitochondrial CB1 receptors regulate neuronal energy metabolism. Nat Neurosci 15(4):558–564. https://doi.org/10.1038/nn.3053CrossRefPubMed

Berg T, Kaur L, Risnes A et al (2016) Determination of a selection of synthetic cannabinoids and metabolites in urine by UHPSFC-MS/MS and by UHPLC-MS/MS. Drug Test Anal 8:708–722. https://doi.org/10.1002/dta.1844CrossRefPubMed

Bilel S, Tirri M, Arfe R et al (2020) Novel halogenated synthetic cannabinoids impair sensorimotor functions in mice. Neurotoxicology 76:17–32. https://doi.org/10.1016/j.neuro.2019.10.002CrossRefPubMed

Canazza I, Ossato A, Trapella C et al (2016) Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on “tetrad”, sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies. Psychopharmacology 233:3685–3709. https://doi.org/10.1007/s00213-016-4402-yCrossRefPubMed

Canazza I, Ossato A, Vincenzi F et al (2017) Pharmaco-toxicological effects of the novel third-generation fluorinate synthetic cannabinoids, 5F-ADBINACA, AB-FUBINACA, and STS-135 in mice. In vitro and in vivo studies. Hum Psychopharmacol 32:e2601. https://doi.org/10.1002/hup.2601

Castaneto MS, Gorelick DA, Desrosiers NA et al (2014) Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 144:12–41. https://doi.org/10.1016/j.drugalcdep.2014.08.005CrossRefPubMed

Ciaglia E, Torelli G, Pisanti S et al (2015) Cannabinoid receptor CB1 regulates STAT3 activity and its expression dictates the responsiveness to SR141716 treatment in human glioma patients' cells. Oncotarget 6(17):15464–15481. https://doi.org/10.18632/oncotarget.3895

Chimalakonda KC, Seely KA, Bratton SM et al (2012) Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids. Am Soc Pharmacol Exp Ther 41:2174–2184

Coccini T, De Simone U, Roccio M et al (2019a) In vitro toxicity screening of magnetite nanoparticles by applying mesenchymal stem cells derived from human umbilical cord lining. J Appl Toxicol 39:1320–1336. https://doi.org/10.1002/jat.3819CrossRefPubMed

Coccini T, Vecchio S, Crevani M, De Simone U (2019b) Cytotoxic effects of 3,4-catechol-pv (one major mdpv metabolite) on human dopaminergic SH-SY5Y cells. Neurotox Res 35(1):49–62. https://doi.org/10.1007/s12640-018-9924-0CrossRefPubMed

Coccini T, Pignatti P, Spinillo A, De Simone U (2020) Developmental neurotoxicity screening for nanoparticles using neuron-like cells of human umbilical cord mesenchymal stem cells: example with magnetite nanoparticles. Nanomaterials 10:1–28. https://doi.org/10.3390/nano10081607CrossRef

Costain WJ, Tauskela JS, Rasquinha I et al (2016) Pharmacological characterization of emerging synthetic cannabinoids in HEK293T cells and hippocampal neurons. Eur J Pharmacol 786:234–245. https://doi.org/10.1016/j.ejphar.2016.05.040CrossRefPubMed

Couceiro J, Bandarra S, Sultan H et al (2016) Toxicological impact of JWH-018 and its phase I metabolite N-(3-hydroxypentyl) on human cell lines. Forensic Sci Int 264:100–105. https://doi.org/10.1016/j.forsciint.2016.03.024CrossRefPubMed

De Petrocellis L, Di Marzo V (2009) Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. J Neuroimmune Pharmacol 5(1):103–121. https://doi.org/10.1007/s11481-009-9177-zCrossRefPubMed

De Simone U, Spinillo A, Caloni F et al (2020) Neuron-like cells generated from human umbilical cord lining-derived mesenchymal stem cells as a new in vitro model for neuronal toxicity screening: using magnetite nanoparticles as an example. Int J Mol Sci 21(1):271. https://doi.org/10.3390/ijms21010271CrossRef

Derungs A, Schwaninger AE, Mansella G et al (2013) Symptoms, toxicities, and analytical results for a patient after smoking herbs containing the novel synthetic cannabinoid MAM-2201. Forensic Toxicol 31:164–171. https://doi.org/10.1007/s11419-012-0166-1CrossRef

Dhawan J, Deng H, Gatley SJ et al (2006) Evaluation of the in vivo receptor occupancy for the behavioral effects of cannabinoids using a radiolabeled cannabinoid receptor agonist, R-[125/131I]AM2233. Synapse 60:93–101. https://doi.org/10.1002/syn.20277CrossRefPubMed

Dinis-Oliveira RJ, Magalhães T (2020) Abuse of licit and illicit psychoactive substances in the workplace: medical, toxicological, and forensic aspects. J Clin Med 9(3):770. https://doi.org/10.3390/jcm9030770CrossRefPubMedCentral

Dobaja M, Grenc D, Kozelj G, Brvar M (2017) Occupational transdermal poisoning with synthetic cannabinoid cumyl-PINACA. Clin Toxicol 55(3):193–195. https://doi.org/10.1080/15563650.2016.1278224CrossRef

Drug Policy Department Italian Presidency of the Council of Ministers (2013) New psychoactive substances. Rome

Dutheil F, Dauchy S, Diry M et al (2009) Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. Drug Metab Dispos 37:1528–1538CrossRef

EMCDDA (2015) Trends and Developments (European Drug Report). http://www.emcdda.europa.eu/publications/edr/trends-developments/2015

EMCDDA (2018) Fentanils and synthetic cannabinoids: driving greater complexity into the drug situation. An update from the EU Early Warning System

Ferguson CS, Tyndale RF (2011) Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. Trends Pharmacol Sci 32(12):708–714. https://doi.org/10.1016/j.tips.2011.08.005CrossRefPubMedPubMedCentral

Frone MR (2011) Alcohol and illicit drug use in the workforce and workplace. In: Quick JC, Tetrick LE (eds) Handbook of Occupational Health Psychology. American Psychological Association, Washington, DC, pp 277–296

Giorgetti A, Busardò FP, Tittarelli R et al (2020) Post-mortem toxicology: a systematic review of death cases involving synthetic cannabinoid receptor agonists. Front Psychiatry 11:1–22. https://doi.org/10.3389/fpsyt.2020.00464CrossRef

Hess C, Stockhausen S, Kernbach-Wighton G et al (2015) Death due to diabetic ketoacidosis: Induction by the consumption of synthetic cannabinoids? Case Reports Forensic Sci Int 257:e6-e11. https://doi.org/10.1016/j.forsciint.2015.08.012

Huestis MA, Gorelick DA, Heishman SJ et al (2001) Blockade of effects of smoked marijuana by the CBl-selective cannabinoid receptor antagonist SR141716. Arc Gen Psychiatry 58:322–328. https://doi.org/10.1001/archpsyc.58.4.322CrossRef

Howlett AC, Barth F, Bonner TI et al (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors Pharmacol Rev 54:161–202. https://doi.org/10.1124/pr.54.2.161CrossRefPubMed

Irie T, Kikura-Hanajiri R, Usami M et al (2015) MAM-2201, a synthetic cannabinoid drug of abuse, suppresses the synaptic input to cerebellar Purkinje cells via activation of presynaptic CB1 receptors. Neuropharmacology 95:479–491. https://doi.org/10.1016/j.neuropharm.2015.02.025CrossRefPubMed

Jacobsson SOP, Wallin T, Fowler CJ (2001) Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J Pharmacol Exp Ther 299:951–959PubMed

Jang M, Shin I, Yang W et al (2014) Determination of major metabolites of MAM-2201 and JWH-122 in in vitro and in vivo studies to distinguish their intake. Forensic Sci Int 244:85–91. https://doi.org/10.1016/j.forsciint.2014.08.008CrossRefPubMed

Jorfi M, D’Avanzo C, Kim DY, Irimia D (2018) Three-dimensional models of the human brain development and diseases. Adv Healthc Mater 7:1–36. https://doi.org/10.1002/adhm.201700723CrossRef

Kim J, Park Y, Park M et al (2015) Simultaneous determination of five naphthoylindole-based synthetic cannabinoids and metabolites and their deposition in human and rat hair. J Pharm Biomed Anal 102:162–175. https://doi.org/10.1016/j.jpba.2014.09.013CrossRefPubMed

Kim JH, Kong TY, Moon JY et al (2018) Targeted and non-targeted metabolite identification of MAM-2201 in human, mouse, and rat hepatocytes. Drug Test Anal 10:1328–1335. https://doi.org/10.1002/dta.2389CrossRef

Koller VJ, Zlabinger GJ, Auwärter V et al (2013) Toxicological profiles of selected synthetic cannabinoids showing high binding affinities to the cannabinoid receptor subtype CB1. Arch Toxicol 87:1287–1297. https://doi.org/10.1007/s00204-013-1029-1CrossRefPubMed

Koller VJ, Auwärter V, Grummt T et al (2014) Investigation of the in vitro toxicological properties of the synthetic cannabimimetic drug CP-47,497–C8. Toxicol Appl Pharmacol 277(2):164–171. https://doi.org/10.1016/j.taap.2014.03.014CrossRefPubMed

Kong TY, Kim JH, Choi WG et al (2017) Metabolic characterization of (1-(5-fluoropentyl)-1H-indol-3-yl)(4-methyl-1-naphthalenyl)-methanone (MAM-2201) using human liver microsomes and cDNA-overexpressed cytochrome P450 enzymes. Anal Bioanal Chem 409:1667–1680. https://doi.org/10.1007/s00216-016-0113-9CrossRefPubMed

Kozela E, Juknat A, Vogel Z (2017) Modulation of astrocyte activity by cannabidiol, a nonpsychoactive cannabinoid. Int J Mol Sci 18(8):1669. https://doi.org/10.3390/ijms18081669CrossRefPubMedCentral

Kronstrand R, Roman M, Andersson M, Eklund A (2013) Toxicological findings of synthetic cannabinoids in recreational users. J Anal Toxicol 37:534–541. https://doi.org/10.1093/jat/bkt068CrossRefPubMed

Kronstrand R, Guerrieri D, Vikingsson S et al (2018) Fatal poisonings associated with new psychoactive substances. Handb Exp Pharmacol 252:495–541. https://doi.org/10.1007/164_2018_110CrossRefPubMed

Lonati D, Buscaglia E, Papa P et al (2014) MAM-2201 (analytically confirmed) intoxication after “synthacaine” consumption. Ann Emerg Med 64:629–632. https://doi.org/10.1016/j.annemergmed.2014.01.007CrossRefPubMed

Mann A, Tyndale RF (2010) Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells. European J Neurosci 31:1185–1193CrossRef

McMillan DM, Tyndale RF (2018) CYP-mediated drug metabolism in the brain impacts drug response. Pharmacol Ther 184:189–200. https://doi.org/10.1016/j.pharmthera.2017.10.008CrossRefPubMed

Miksys S, Tyndale RF (2013) 2011 CCNP Heinz Lehmann Award paper: cytochrome P450-mediated drug metabolism in the brain. J Psychiatry Neurosci 38(3):152–163. https://doi.org/10.1503/jpn.120133CrossRefPubMedPubMedCentral

Miliano C, Serpelloni G, Rimondo C et al (2016) Neuropharmacology of new psychoactive substances (NPS): focus on the rewarding and reinforcing properties of cannabimimetics and amphetamine-like stimulants. Front Neurosci 10:153. https://doi.org/10.3389/fnins.2016.00153CrossRefPubMedPubMedCentral

Müller H, Sperling W, Köhrmann M et al (2010) The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res 118:309–310. https://doi.org/10.1016/j.schres.2009.12.001CrossRefPubMed

Ossato A, Canazza I, Trapella C et al (2016) Effect of JWH-250, JWH-073 and their interaction on “tetrad”, sensorimotor, neurological and neurochemical responses in mice. Prog Neuropsychopharmacol Biol Psychiatry 67:31–50. https://doi.org/10.1016/j.pnpbp.2016.01.007CrossRefPubMed

Pereira CVM (2014) Assessment of neuronal cytotoxicity of Jwh-073 and Jwh-250. Master's Degree Thesis. Instituto Superior De Ciências Da Saúde Egas Moniz

Presgraves SP, Ahmed T, Borwege S, Joyce JN (2003) Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists. Neurotox Res 5:579–598. https://doi.org/10.1007/BF03033178CrossRef

Sachdev S, Vemuri K, Banister SD et al (2019) In vitro determination of the efficacy of illicit synthetic cannabinoids at CB1 receptors. Br J Pharmacol 176:4653–4665. https://doi.org/10.1111/bph.14829CrossRefPubMedPubMedCentral

Saito T, Namera A, Miura N et al (2013) A fatal case of MAM-2201 poisoning. Forensic Toxicol 31:333–337. https://doi.org/10.1007/s11419-013-0190-9CrossRef

Sambuy Y, Alloisio S, Bertanza G et al (2018) Air, water and soil: Which alternatives? Alternative models in environmental toxicology. ALTEX 35:254–256. https://doi.org/10.14573/altex.1802121

Sánchez C, Galve-Roperh I, Canova C et al (1998) Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett 436(1):6–10. https://doi.org/10.1016/s0014-5793(98)01085-0CrossRefPubMed

Schaefer N, Peters B, Bregel D et al (2013) A fatal case involving several synthetic cannabinoids. Toxichem Krimtech 80(Special Issue):248–251

Schaefer N, Nordmeier F, Kröll A-K et al (2020) Is adipose tissue suitable for detection of (synthetic) cannabinoids? A comparative study analyzing antemortem and postmortem specimens following pulmonary administration of JWH-210, RCS-4, as well as ∆⁹-tetrahydrocannabinol to pigs. Arch Toxicol 94(10):3421–3431. https://doi.org/10.1007/s00204-020-02843-xCrossRefPubMedPubMedCentral

Scheau C, Badarau IA, Mihai LG et al (2020) Cannabinoids in the Pathophysiology of Skin Inflammation. Molecules 25(3):652. https://doi.org/10.3390/molecules25030652CrossRefPubMedCentral

Scheidweiler KB, Jarvis MJY, Huestis MA (2015) Nontargeted SWATH acquisition for identifying 47 synthetic cannabinoid metabolites in human urine by liquid chromatography-high-resolution tandem mass spectrometry. Anal Bioanal Chem 407:883–897. https://doi.org/10.1007/s00216-014-8118-8CrossRefPubMed

Seely KA, Brents LK, Radominska-Pandya A et al (2012) A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors. Chem Res Toxicol 25(4):825–827. https://doi.org/10.1021/tx3000472CrossRefPubMedPubMedCentral

Sezer Y, Jannuzzi AT, Huestis MA, Alpertunga B (2020) In vitro assessment of the cytotoxic, genotoxic and oxidative stress effects of the synthetic cannabinoid JWH-018 in human SH-SY5Y neuronal cells. Toxicol Res (Camb) 9(6):734–740. https://doi.org/10.1093/toxres/tfaa078CrossRef

Sewell F, Doe J, Gellatly N et al (2017) Steps towards the international regulatory acceptance of non-animal methodology in safety assessment. Regul Toxicol Pharmacol 89:50–56. https://doi.org/10.1016/j.yrtph.2017.07.001CrossRefPubMed

Simaõ D, Terrasso AP, Teixeira AP et al (2016) Functional metabolic interactions of human neuron-astrocyte 3D in vitro networks. Sci Rep 6:1–12. https://doi.org/10.1038/srep33285CrossRef

Soderstrom K, Soliman E, Van Dross R (2017) Cannabinoids modulate neuronal activity and cancer by CB1 and CB2 receptor-independent mechanisms. Front Pharmacol 8:720. https://doi.org/10.3389/fphar.2017.00720CrossRefPubMedPubMedCentral

Stella N (2010) Cannabinoid and cannabinoid-like receptors in microglia, astrocytes and astrocytomas. Glia 58(9):1017–1030. https://doi.org/10.1002/glia.20983CrossRefPubMedPubMedCentral

Tapp L, Ramsey JG, Wen A, Gerona R (2017) Synthetic cannabinoid and mitragynine exposure of law enforcement agents during the raid of an illegal laboratory - Nevada, 2014. MMWR Morb Mortal Wkly Rep 66(47): 1291–1294. https://doi.org/10.15585/mmwr.mm6647a3

Tauskela JS, Comas T, Hewitt M et al (2016) Effect of synthetic cannabinoids on spontaneous neuronal activity: evaluation using Ca²⁺ spiking and multi-electrode arrays. Eur J Pharmacol 786:148–160. https://doi.org/10.1016/j.ejphar.2016.05.038CrossRefPubMed

Tomiyama K, Funada M (2011) Cytotoxicity of synthetic cannabinoids found in “Spice” products: the role of cannabinoid receptors and the caspase cascade in the NG 108–15 cell line. Toxicol Lett 207:12–17. https://doi.org/10.1016/j.toxlet.2011.08.021CrossRefPubMed

Tomiyama K, Funada M (2014) Cytotoxicity of synthetic cannabinoids on primary neuronal cells of the forebrain: The involvement of cannabinoid CB1 receptors and apoptotic cell death. Toxicol Appl Pharmacol 274:17–23. https://doi.org/10.1016/j.taap.2013.10.028CrossRefPubMed

Tukker AM, De Groot MWGDM, Wijnolts FMJ et al (2016) Research article is the time right for in vitro neurotoxicity testing using human iPSC-derived neurons? ALTEX 33:261–271. https://doi.org/10.14573/altex.1510091

Uchiyama N, Kikura-Hanajiri R, Ogata J, Goda Y (2010) Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci Int 198:31–38. https://doi.org/10.1016/j.forsciint.2010.01.004CrossRefPubMed

Uchiyama N, Kawamura M, Kikura-Hanajiri R, Goda Y (2011) Identification and quantitation of two cannabimimetic phenylacetylindoles JWH-251 and JWH-250, and four cannabimimetic naphthoylindoles JWH-081, JWH-015, JWH-200, and JWH-073 as designer drugs in illegal products. Forensic Toxicol 29:25–37. https://doi.org/10.1007/s11419-010-0100-3CrossRef

UNODC (2013) World Drug Report. Vienna

UNODC (2014) Early Warning Advisory on NPS. Vienna

Valente MJ, Araújo AM, de Lourdes BM et al (2016) Editor’s Highlight: characterization of hepatotoxicity mechanisms triggered by designer cathinone drugs (β-Keto Amphetamines). Toxicol Sci 153:89–102. https://doi.org/10.1093/toxsci/kfw105CrossRefPubMed

Valente MJ, Amaral C, Correia-da-Silva G et al (2017) Methylone and MDPV activate autophagy in human dopaminergic SH-SY5Y cells: a new insight into the context of β-keto amphetamines-related neurotoxicity. Arch Toxicol 91:3663–3676. https://doi.org/10.1007/s00204-017-1984-zCrossRefPubMed

Van Amsterdam J, Brunt T, Van Den Brink W (2015) The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol 29:254–263. https://doi.org/10.1177/0269881114565142CrossRefPubMed

Vigolo A, Ossato A, Trapella C et al (2015) Novel halogenated derivates of JWH-018: behavioral and binding studies in mice. Neuropharmacology 95:68–82. https://doi.org/10.1016/j.neuropharm.2015.02.008CrossRefPubMed

Wang Z, Wang SN, Xu TY et al (2017) Organoid technology for brain and therapeutics research. CNS Neurosci Ther 23:771–778. https://doi.org/10.1111/cns.12754CrossRefPubMedPubMedCentral

Wiebelhaus JM, Poklis JL, Poklis A et al (2012) Inhalation exposure to smoke from synthetic “marijuana” produces potent cannabimimetic effects in mice. Drug Alcohol Depend 126:316–323. https://doi.org/10.1016/j.drugalcdep.2012.05.034CrossRefPubMedPubMedCentral

Wiley JL, Marusich JA, Lefever TW et al (2015) AB-CHMINACA, AB-PINACA, and FUBIMINA: affinity and potency of novel synthetic cannabinoids in producing Δ⁹-Tetrahydrocannabinol-like effects in mice. J Pharmacol Exp Ther 354:328–339. https://doi.org/10.1124/jpet.115.225326CrossRefPubMedPubMedCentral

Wiley JL, Lefever TW, Marusich JA et al (2016) Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in vivo assays in mice. Neuropharmacology 110(Pt A):143–153. https://doi.org/10.1016/j.neuropharm.2016.07.016CrossRefPubMedPubMedCentral

Wojcieszak J, Andrzejczak D, Woldan-Tambor A, Zawilska JB (2016a) Cytotoxic activity of pyrovalerone derivatives, an emerging group of psychostimulant designer cathinones. Neurotox Res 30(2):239–250. https://doi.org/10.1007/s12640-016-9640-6CrossRefPubMed

Wojcieszak J, Krzemień W, Zawilska JB (2016b) JWH-133, a selective cannabinoid cb2 receptor agonist, exerts toxic effects on neuroblastoma SH-SY5Y cells. J Mol Neurosci 58:441–445. https://doi.org/10.1007/s12031-016-0726-7CrossRefPubMed

Yin X, Mead BE, Helia S et al (2017) Stem cell organoid engineering. Cell Stem Cell 18:25–38. https://doi.org/10.1016/j.stem.2015.12.005.StemCrossRef

Zaitsu K, Hayashi Y, Suzuki K et al (2015a) Metabolome disruption of the rat cerebrum induced by the acute toxic effects of the synthetic cannabinoid MAM-2201. Life Sci 137:49–55. https://doi.org/10.1016/j.lfs.2015.05.013CrossRefPubMed

Zaitsu K, Nakayama H, Yamanaka M et al (2015b) High-resolution mass spectrometric determination of the synthetic cannabinoids MAM-2201, AM-2201, AM-2232, and their metabolites in postmortem plasma and urine by LC/Q-TOFMS. Int J Legal Med 129:1233–1245. https://doi.org/10.1007/s00414-015-1257-4CrossRefPubMed

Titel: MAM-2201, One of the Most Potent—Naphthoyl Indole Derivative—Synthetic Cannabinoids, Exerts Toxic Effects on Human Cell-Based Models of Neurons and Astrocytes
verfasst von: T Coccini
U De Simone
D Lonati
G Scaravaggi
M Marti
CA Locatelli
Publikationsdatum: 01.08.2021
Verlag: Springer US
Erschienen in: Neurotoxicity Research / Ausgabe 4/2021
Print ISSN: 1029-8428
Elektronische ISSN: 1476-3524
DOI: https://doi.org/10.1007/s12640-021-00369-3

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2021

Immune-Regulatory and Molecular Effects of Antidepressants on the Inflamed Human Keratinocyte HaCaT Cell Line

Chronic Cyanuric Acid Exposure Depresses Hippocampal LTP but Does Not Disrupt Spatial Learning or Memory in the Morris Water Maze

Protective Effect of Aldo–keto Reductase 1B1 Against Neuronal Cell Damage Elicited by 4′-Fluoro-α-pyrrolidinononanophenone

Differential Influence of Amyloid-β on the Kinetics of Dopamine Release in the Dorsal and Ventral Striatum of Rats

Potential of Amantadine to Ameliorate Glutamate-Induced Pyramidal Cells Toxicity in Juvenile Rat’ Brain Cortex